Key terms

About CHRS

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest CHRS news

Mar 20 6:16am ET Buy Rating on Coherus Biosciences: Balancing Divestiture with Promising Pipeline and Financial Growth Mar 20 6:06am ET Coherus Biosciences price target lowered to $11 from $13 at H.C. Wainwright Mar 14 8:30pm ET Analysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Solid Biosciences (SLDB) Mar 14 1:40pm ET Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Coherus Biosciences (CHRS) and Autolus Therapeutics (AUTL) Mar 14 7:30am ET Analysts Conflicted on These Healthcare Names: Amedisys (AMED), Cytokinetics (CYTK) and Coherus Biosciences (CHRS) Mar 14 6:15am ET Buy Rating Affirmed for Coherus Biosciences on Strong Sales and Strategic Restructuring Mar 13 4:11pm ET Coherus Biosciences reports Q4 EPS (62c), consensus (12c) Mar 13 2:49pm ET Coherus BioSciences options imply 21.5% move in share price post-earnings Mar 13 8:05am ET Options Volatility and Implied Earnings Moves Today, March 13, 2024 Mar 04 6:35am ET Sandoz acquires CIMERLI business from Coherus BioSciences Feb 22 5:13pm ET Coherus Biosciences Appoints New Director, Boosts Governance Feb 21 8:31am ET Coherus Biosciences announces U.S. launch of UDENYCA ONBODY Feb 06 4:22am ET Coherus Biosciences Announces Key Consent and Amendment Feb 06 4:21am ET Coherus Biosciences Amends Loan Terms with Biopharma Feb 05 8:20am ET Coherus Biosciences amends term loan agreement with Pharmakon Jan 29 5:07am ET Barclays Sticks to Their Buy Rating for Coherus Biosciences (CHRS) Jan 25 11:38am ET Biotech Alert: Searches spiking for these stocks today Jan 25 11:38am ET Biotech Alert: Searches spiking for these stocks today Jan 24 11:08am ET Biotech Alert: Searches spiking for these stocks today Jan 23 9:17am ET Coherus Biosciences price target lowered to $8 from $12 at Truist Jan 23 6:15am ET Coherus Biosciences price target lowered to $9 from $11 at Baird Jan 23 3:09am ET Coherus Biosciences Announces New Purchase Agreement Details Jan 23 3:09am ET Coherus BioSciences Sells CIMERLI® Franchise to Sandoz Jan 22 3:17pm ET Promising Clinical Advances and Market Potential Uphold Buy Rating for Coherus Biosciences Jan 22 2:42pm ET Barclays Gives a Buy Rating to Coherus Biosciences (CHRS) Jan 22 1:29pm ET Buy Rating Affirmed for Coherus Biosciences on Strong Clinical Data and Strategic Pipeline Positioning Jan 22 7:03am ET Coherus (NASDAQ:CHRS) Surges After $170M Deal with Sandoz for CIMERLI Franchise Jan 22 6:35am ET Sandoz agrees to acquire Cimerli business from Coherus Jan 18 4:28pm ET Coherus Biosciences presents positive Phase 2 data on casdozokitu Jan 11 6:30am ET Analysts Offer Insights on Healthcare Companies: LifeMD (LFMD) and Coherus Biosciences (CHRS) Jan 04 8:07am ET Inovio, Coherus Biosciences announces clinical collaboration

No recent press releases are available for CHRS

CHRS Financials

1-year income & revenue

Key terms

CHRS Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

CHRS Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms